Harvard Bioscience Q1 Adj $0.02, Inline, Sales $24.51M Miss $25.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience reported Q1 adjusted earnings of $0.02 per share, meeting analyst estimates but marking a 66.67% decrease from last year. Sales were $24.51M, missing the $25.79M estimate and down 18.23% from the previous year.
May 07, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harvard Bioscience's Q1 earnings matched expectations but showed a significant decrease from the previous year, with sales also falling short of estimates.
The reported earnings and sales miss, especially with a significant year-over-year decrease, are likely to negatively impact investor sentiment and could lead to a short-term decrease in HBIO's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100